Repurposing FDA-Approved Antimalarial Drugs: Mefloquine as a Promising Multi-Targeted Therapeutic for Non-Small Cell Lung Cancer: Repurposing Antimalarials: Mefloquine for Multi-Targeted NSCLC Therapy. IJC [Internet]. 2025 Jul. 24 [cited 2026 May 14];64(7):730-45. Available from: https://or.niscpr.res.in/index.php/IJC/article/view/16642